The pharmacological properties of the novel peptide BPC 157 (PL-10).
Sikiric. P P
Key Findings
- BPC‑157 promotes healing of gastrointestinal lesions and protects the stomach lining.
- The peptide shows protective effects on pancreas, liver, heart (including rhythm disturbances) and blood pressure.
- It aids wound, fracture, and pseudo‑arthrosis healing, possibly by modulating dopamine, nitric‑oxide, prostaglandin, and somatosensory pathways.
Practical Outcomes
- For biohackers, the take‑away is that BPC‑157 may be a useful add‑on for recovery and tissue repair, especially after injuries or gut stress. However, the review does not provide concrete dosing guidelines or human safety data, so any use should start with low doses and be monitored closely. More research, especially in people, is needed before definitive protocols can be recommended.
Summary
BPC‑157 is a small peptide that, in many animal experiments, has been shown to protect and help heal a wide range of tissues – from the gut and liver to the heart, blood vessels, wounds, and even broken bones. It appears to work by balancing several body signaling systems like dopamine, nitric‑oxide and prostaglandins, which are involved in inflammation and tissue repair. The paper is a review of these findings, so it doesn’t give specific dosing or human data, but it supports the idea that BPC‑157 could be a broad‑spectrum healing agent.
Abstract
The reported beneficial effects of the gastric mucosal derived pentadecapeptide BPC 157 (Gly Glu Pro Pro Pro Gly Lys Pro Ala Asp Asp Ala Gly Leu Val, M.W. 1419) on different organ lesions are reviewed. Apart from the effects on various gastrointestinal lesions, the potentially beneficial effect on pancreas, liver injuries, endothelium and heart damage, i.e. dysrhythmias following reoxygenation, and blood pressure, along with effect on experimental acute/chronic inflammation, wound and fracture (pseudoarthrosis) healing are described. It appears that these beneficial effects all together provide a particular network reflecting activity of a special peptidergic defence system. In support of this concept, it appears that there are interactions of this pentadecapeptide with many important systems (namely, dopamine-, NO-, prostaglandin-, somatosensory neurone-systems), that could provide a basis for the observed protective effects. Moreover, since disturbance of these systems' functions (i.e. dopamine-, NO-, somatosensory neuronal-system) which manifest either over-activity or as inhibition, may contribute to the multiple lesions in different organs. The reported evidence that this pentadecapeptide is able to counteract both their over-action, and their inhibition, may suggest this pentadecapeptide as a new, but most probably essential physiological defence system and that should be further investigated.
Study Information
pubmed
1999
10.1007/s10787-999-0022-z
7
41